Zanubrutinib
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
Zanubrutinib: From Mantle Cell Lymphoma to Myeloid Leukemia
One-Sentence Summary
Zanubrutinib is a BTK inhibitor originally used for B-cell malignancies such as mantle cell lymphoma. The TxGNN model predicts it may be effective for myeloid leukemia, but the data compiled for this report show only 1 early-phase clinical trial (where zanubrutinib is a combination partner) and no myeloid-specific publications, so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mantle cell lymphoma, B-cell neoplasm, lymphosarcoma |
| Predicted New Indication | Myeloid leukemia |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L4 |
| US Market Status | Cancelled only (the two listed NDAs are cancelled) |
| Number of NDAs | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Zanubrutinib is known as a next-generation, highly selective BTK inhibitor, and its efficacy in B-cell malignancies is supported by the literature, including CLL/SLL and Waldenström macroglobulinemia.
The link to myeloid leukemia is only indirect. BTK is expressed in myeloid lineage cells and contributes to signaling independent of the B-cell receptor, so shared pathway biology could make the drug relevant. However, all supplied literature concerns B-cell malignancies, not myeloid leukemia. The high TxGNN score is a computational prediction and is not backed by myeloid-specific clinical data.
The other predicted indications (vertebral anomalies with endocrine and T-cell dysfunction, ganglioneuroblastoma, retroperitoneal neoplasm, Ewing sarcoma, neuroblastoma) have no supporting trials or meaningful literature and appear to be knowledge-graph artifacts.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05665530 | Phase 1 | Completed | 86 | Dose-escalation safety study of PRT2527 (a CDK9 inhibitor) alone and combined with zanubrutinib or venetoclax in relapsed/refractory hematologic malignancies. Zanubrutinib is only a combination partner; no myeloid-leukemia-specific efficacy result is available. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39647999 | 2025 | RCT | J Clin Oncol | SEQUOIA (Phase 3), 5-year follow-up: zanubrutinib vs bendamustine + rituximab in treatment-naïve CLL/SLL |
| 36400069 | 2023 | Cohort | Lancet Haematol | Phase 2 single-arm study in B-cell malignancies intolerant of prior BTK inhibitors |
| 40334067 | 2025 | Cohort | Blood Adv | Updated results: well tolerated and effective in CLL/SLL intolerant of ibrutinib/acalabrutinib |
| 40829104 | 2026 | Cohort | Blood Adv | Pooled analysis across studies in CLL/SLL with del(17p) and/or TP53 mutations (N = 301) |
| 36402930 | 2023 | Review | Leukemia | BTK inhibitors for managing Waldenström macroglobulinemia |
| 37150651 | 2023 | Review | Clin Lymphoma Myeloma Leuk | Hepatitis B virus reactivation in patients receiving BTK inhibitors |
| 42192981 | 2026 | Review | Cancers | BTK inhibitors in CLL: hypogammaglobulinemia and infection risk |
| 34959482 | 2021 | Review | Pharmaceutics | Overview of tyrosine kinase inhibitors in chronic leukemias (CML and CLL) |
| 38288815 | 2024 | Review | Anticancer Agents Med Chem | Synthetic methods of FDA-approved anticancer drugs; no disease-specific evidence |
| 36325357 | 2022 | Case report | Front Immunol | Rare coexisting Waldenström macroglobulinemia and B-cell ALL |
None of these publications reports zanubrutinib efficacy in myeloid leukemia.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA218785 | BRUKINSA | Film-coated tablet | Not available (status: cancelled) |
| NDA213217 | BRUKINSA | Capsule | Not available (status: cancelled) |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BTK inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; CBC and liver function are generally monitored for oncology kinase inhibitors |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the data compiled for this report. Examples of Major interactions include aprepitant, acetylsalicylic acid, dexamethasone, clarithromycin, cobicistat, deferasirox, deferiprone, samarium (153Sm) lexidronam, ibritumomab tiuxetan and tositumomab (I-131). Examples of Moderate interactions include cimetidine, miconazole, clotrimazole, metreleptin, fenfluramine and sibutramine.
- Literature-noted risks: Hepatitis B virus reactivation and hypogammaglobulinemia with increased infection risk have been described for BTK inhibitors.
For other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests mainly on a high model score. The only trial is an early Phase 1 study in which zanubrutinib is a combination partner, and all supporting literature concerns B-cell malignancies rather than myeloid leukemia. Both US NDAs are also listed as cancelled.
To proceed, the following is needed:
- Detailed mechanism-of-action data and a mechanistic rationale for BTK dependence in myeloid leukemia
- Preclinical data in myeloid leukemia models
- Results or subgroup data from NCT05665530 relevant to myeloid disease
- Package insert warnings and contraindications for safety screening
- Clarification of the cancelled US NDA status and the approved indication text
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.